BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29559278)

  • 1. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
    Gingipalli L; Block MH; Bao L; Cooke E; Dakin LA; Denz CR; Ferguson AD; Johannes JW; Larsen NA; Lyne PD; Pontz TW; Wang T; Wu X; Wu A; Zhang HJ; Zheng X; Dowling JE; Lamb ML
    Bioorg Med Chem Lett; 2018 May; 28(8):1336-1341. PubMed ID: 29559278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
    Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.
    Pierre F; Regan CF; Chevrel MC; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Rice WG; Ryckman DM
    Bioorg Med Chem Lett; 2012 May; 22(9):3327-31. PubMed ID: 22460033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and structure-activity relationship of 2,6-disubstituted pyrazines, potent and selective inhibitors of protein kinase CK2.
    Fuchi N; Iura Y; Kaneko H; Nitta A; Suyama K; Ueda H; Yamaguchi S; Nishimura K; Fujii S; Sekiya Y; Yamada M; Takahashi T
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4358-61. PubMed ID: 22633690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.
    Cozza G; Girardi C; Ranchio A; Lolli G; Sarno S; Orzeszko A; Kazimierczuk Z; Battistutta R; Ruzzene M; Pinna LA
    Cell Mol Life Sci; 2014 Aug; 71(16):3173-85. PubMed ID: 24442476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
    More KN; Hong VS; Lee A; Park J; Kim S; Lee J
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of pyrazine-based CK2 inhibitors: synthesis and evaluation of 2,6-disubstituted pyrazines and 4,6-disubstituted pyrimidines.
    Suzuki Y; Cluzeau J; Hara T; Hirasawa A; Tsujimoto G; Oishi S; Ohno H; Fujii N
    Arch Pharm (Weinheim); 2008 Sep; 341(9):554-61. PubMed ID: 18763715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
    Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
    Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
    Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
    Wang HL; Cee VJ; Chavez F; Lanman BA; Reed AB; Wu B; Guerrero N; Lipford JR; Sastri C; Winston J; Andrews KL; Huang X; Lee MR; Mohr C; Xu Y; Zhou Y; Tasker AS
    Bioorg Med Chem Lett; 2015 Feb; 25(4):834-40. PubMed ID: 25597005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pim kinase inhibitory and antiproliferative activity of a novel series of meridianin C derivatives.
    More KN; Jang HW; Hong VS; Lee J
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2424-8. PubMed ID: 24775304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
    Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
    Wu B; Wang HL; Cee VJ; Lanman BA; Nixey T; Pettus L; Reed AB; Wurz RP; Guerrero N; Sastri C; Winston J; Lipford JR; Lee MR; Mohr C; Andrews KL; Tasker AS
    Bioorg Med Chem Lett; 2015 Feb; 25(4):775-80. PubMed ID: 25616902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
    López-Ramos M; Prudent R; Moucadel V; Sautel CF; Barette C; Lafanechère L; Mouawad L; Grierson D; Schmidt F; Florent JC; Filippakopoulos P; Bullock AN; Knapp S; Reiser JB; Cochet C
    FASEB J; 2010 Sep; 24(9):3171-85. PubMed ID: 20400536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
    Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
    Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
    Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.
    Mortensen DS; Perrin-Ninkovic SM; Shevlin G; Elsner J; Zhao J; Whitefield B; Tehrani L; Sapienza J; Riggs JR; Parnes JS; Papa P; Packard G; Lee BG; Harris R; Correa M; Bahmanyar S; Richardson SJ; Peng SX; Leisten J; Khambatta G; Hickman M; Gamez JC; Bisonette RR; Apuy J; Cathers BE; Canan SS; Moghaddam MF; Raymon HK; Worland P; Narla RK; Fultz KE; Sankar S
    J Med Chem; 2015 Jul; 58(14):5599-608. PubMed ID: 26102506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of pyrazolo[4,3-a]phenanthridines, a new scaffold for Pim kinase inhibition.
    Suchaud V; Gavara L; Giraud F; Nauton L; Théry V; Anizon F; Moreau P
    Bioorg Med Chem; 2014 Sep; 22(17):4704-10. PubMed ID: 25087047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
    Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
    Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.